Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: limit (518), stricture (9), limitation (67), restriction (110), constraint (36), bound (115)

Docetaxel (75) Prednisolone (6 cycles)) Ver1

Description: Chemotherapy Protocol PROSTATE DOCETAXEL(75)-PREDNISOLONE (6 cycles) Regimen Prostate-Docetaxel (75)-Prednisolone (6 cycles) Indication First line treatment of prostate
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Docetaxel-75-Prednisolone-6-cycles-Ver1.pdf

Cabazitaxel-Prednisolone

Description: Chemotherapy Protocol PROSTATE CABAZITAXEL-PREDNISOLONE Regimen • Prostate-Cabazitaxel-Prednisolone Indication • Castrate resistant metastatic prostate cancer previously treated with docetaxel containing regimens
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Cabazitaxel-Prednisolone.pdf

Alectinib

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ALECTINIB Regimen • NSCLC - ALECtinib Indication • Alectinib (as monotherapy) is indicated for first-line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Alectinib.pdf

Rituximab (8 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

Rituximab (12 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (12 weekly) Regimen Lymphoma – Rituximab (12 Weekly) Indication Non- Hodgkin’s Lymphoma as maintenance monotherapy for relapsed
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-12-weekly.pdf

Obinutuzumab_maintenance

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Obinutuzumab (Maintenance) Regimen • NHL – Obinutuzumab (Maintenance) Indication • Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Obinutuzumab-maintenance.pdf

Gemcitabine-Vinorelbine Ver1.1

Description: Chemotherapy Protocol LYMPHOMA GEMCITABINE-VINORELBINE Regimen Lymphoma – Gemcitabine-Vinorelbine Indication Relapsed or refractory Non-Hodgkin’s Lymphoma Relapsed or refractory Hodgkin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Gemcitabine-Vinorelbine-Ver1.1.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclophosphamide-Fludarabine PO
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

FC IV (3 day)-Cyclophosphamide-Fludarabine IV (3 day) Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE–FLUDARABINE INTRAVENOUS (FC IV 3 day) Regimen Lymphoma – FC IV (3 day)- Cyclophosphamide-Fludarabine IV (3 day
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-IV-3-day-Cyclophosphamide-Fludarabine-IV-3-day-Ver-1.1.pdf

CVP-Cyclophosphamide-Prednisolone-Vincristine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-VINCRISTINE (CVP) Regimen Lymphoma – CVP-Cyclophosphamide-Prednisolone-Vincristine Indication Non Hodgkin’s Lymphoma Toxicity Drug Adverse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CVP-Cyclophosphamide-Prednisolone-Vincristine-Ver-1.2.pdf

41 to 50 of 132

Previous … 3 4 5 6 7 … Next